Comment on “New therapeutic agents in diabetic nephropathy”
2
조회
0
다운로드
0
인용
0
참고문헌
초록
We have read with great interest the article “New therapeutic agents in diabetic nephropathy” Korean J Intern Med 2017;32:11-25 by Yaeni Kim and Cheol Whee Park [1]. The authors stated that ‘the Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY) trial using mineralocorticoid receptor blockers (MT-3995, BAY 94-3995, and BAY 94-8862) has shown limited efficacy in the early stages of diabetic nephropathy and concerns regarding the development of hyperkalemia need to be addressed.
Abstract
We have read with great interest the article “New therapeutic agents in diabetic nephropathy” Korean J Intern Med 2017;32:11-25 by Yaeni Kim and Cheol Whee Park [1]. The authors stated that ‘the Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY) trial using mineralocorticoid receptor blockers (MT-3995, BAY 94-3995, and BAY 94-8862) has shown limited efficacy in the early stages of diabetic nephropathy and concerns regarding the development of hyperkalemia need to be addressed.
참고문헌 (3)
- 김예니, "New therapeutic agents in diabetic nephropathy", The Korean Journal of Internal Medicine, 32(1), pp.11~25 (2017), 대한내과학회[DOI]
- Lindhardt M, "Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY):essential study design and rationale of a randomised clinical multicentre trial", BMJ Open, 6, pp.e010310~ (2016)
- Bakris GL, "Effect of finerenone on albuminuria in patients with diabetic nephropathy:a randomized clinical trial", JAMA, 314, pp.884~894 (2015)